A bold new approach to cardio-kidney-metabolic research is taking center stage, and it's time to explore the groundbreaking work of Boehringer Ingelheim. This family-owned company, with its rich 140-year history, is dedicated to improving global health, not just shareholder wealth. At the 2025 American Heart Association Scientific Sessions, Neerja Balachander, MBBS, PhD, unveiled the company's innovative therapies and advancements, showcasing their commitment to this vital area of research.
But here's where it gets controversial: understanding the intricate connection between heart and kidney health is key to early intervention and long-term risk reduction. Balachander highlights the importance of recognizing endothelial dysfunction, which can manifest as protein leakage in the urine due to blood vessel issues. This is a critical sign, often first seen in the kidneys, indicating potential problems in multiple organs.
And this is the part most people miss: kidney disease is a silent killer. Nine out of ten patients are unaware they have it, yet research shows they are at a much higher risk of heart-related complications and death. The solution? A simple, inexpensive test to measure the albumin-to-creatinine ratio in urine. It's a game-changer, and it should be a routine part of patient care, just like checking blood pressure or diabetic status.
So, why aren't we doing this more often? Balachander points to the issue of medical silos and the overwhelming demands on primary care physicians. However, initiatives led by organizations like the National Kidney Foundation, the American Diabetes Association, and the American Heart Association are working to simplify the process and provide clinicians with concise, actionable risk factor lists.
Boehringer Ingelheim is at the forefront of this movement, having pioneered the study of empagliflozin for cardiovascular risk reduction and chronic kidney disease. Their research has expanded to include agents like survodutide for obesity and metabolic-associated steatohepatitis, and they remain committed to developing therapies that address the interconnected nature of cardio-kidney-metabolic diseases.
For Balachander, this work is deeply personal. As a representative of a family-owned company, she emphasizes that their focus is on family and patient health, not Wall Street. With a majority of the world's population suffering from cardio-kidney-metabolic conditions, Boehringer Ingelheim's vision is to improve patient outcomes by addressing these interconnected diseases.
The company's efforts are a testament to their broader vision, and their dedication to advancing therapies across the cardio-renal-metabolic spectrum is a beacon of hope for patients worldwide. So, let's continue the conversation: how can we ensure that these innovative therapies reach those who need them most? What steps can we take to break down the barriers of medical silos and improve patient care?
